Gene therapy vs cell therapy comes down to what is changed: gene therapy modifies genes to treat disease, while cell therapy gives living cells for a therapeutic purpose. The two overlap when a patient’s own cells are genetically modified.
Both approaches sit within stem cell research and the wider field of regenerative medicine, and the regulatory and evidence questions differ for each.
What gene therapy does
The FDA describes gene therapy as a technique that modifies a person’s genes to treat or cure disease. It lists several mechanisms: replacing a disease-causing gene with a healthy copy, inactivating a disease-causing gene that is not functioning properly, or introducing a new or modified gene into the body to help treat a disease.
The target is the genetic instruction itself. The product is the means of delivering or altering that instruction, rather than a population of cells that is expected to act on its own.
MedlinePlus, from the National Library of Medicine, explains that the earliest method, often called gene transfer or gene addition, was developed to introduce a new gene into cells or to introduce a non-faulty copy of a gene to stand in for the altered copy causing disease. A newer technique, genome editing, introduces molecular tools to change the existing DNA in the cell instead of adding new genetic material.
How gene therapy products are delivered
The FDA lists a variety of gene therapy product types: plasmid DNA, viral vectors, bacterial vectors, human gene editing technology and patient-derived cellular gene therapy products. Viruses have a natural ability to deliver genetic material into cells, so some products are derived from viruses that have been modified to remove their ability to cause infectious disease and then used as vectors, or vehicles, to carry therapeutic genes into human cells.
Genome editing has its own goals. According to the FDA, the aims of gene editing are to disrupt harmful genes or to repair mutated genes. The tool most associated with this approach is covered in the guide to CRISPR gene editing.
The FDA adds that gene therapy products are being studied to treat diseases including cancer, genetic diseases, and infectious diseases. Being studied is a statement about research activity, not about results, and each product has to be judged on its own trial data.
What cell therapy does
The FDA’s Center for Biologics Evaluation and Research (CBER) says cellular therapy products include cellular immunotherapies, cancer vaccines, and other types of both autologous and allogeneic cells for certain therapeutic indications, including hematopoietic stem cells and adult and embryonic stem cells. Autologous cells come from the same person who receives them, while allogeneic cells come from a donor.
In cell therapy the living cells are the product. They are expected to engraft, replace, support or signal to other cells, so questions about source, processing, dose and how long the cells persist matter in a way they do not for a gene delivered in a vector.
The oldest and best-established use of this kind is the transplant of blood-forming cells, which is the subject of a separate guide on hematopoietic stem cell transplants. How the broader field developed is traced in the history of stem cell research.
Where the two approaches overlap
The categories are not mutually exclusive. The FDA includes patient-derived cellular gene therapy products among its gene therapy types, in which cells are removed from the patient, genetically modified (often using a viral vector) and then returned to the patient. Such a product is both a gene therapy and a cell therapy.
That overlap is why the regulator handles them together. CBER regulates cellular therapy products, human gene therapy products, and certain devices related to cell and gene therapy, and the agency’s list of approved cellular and gene therapy products is published on one FDA page.
The overlap also shows why labels alone mislead. A product described as a cell therapy may carry a genetic modification, and a product described as a gene therapy may be made by modifying cells outside the body. The description of how the product is made and given, found in a regulator’s listing or a trial record, is more informative than the name used in a news story or an advertisement.
Regulation and evidence
The FDA states that gene therapy products are biological products regulated by CBER. Clinical studies in humans require the submission of an investigational new drug application (IND) before they begin in the United States, and marketing a gene therapy product requires submission and approval of a biologics license application (BLA).
The FDA says that CBER has approved both cellular and gene therapy products, but approval is product-specific and condition-specific. MedlinePlus notes that gene therapies are being used to treat a small number of diseases, including an eye disorder called Leber congenital amaurosis and a muscle disorder called spinal muscular atrophy, and that many more are undergoing research to make sure that they will be safe and effective. It describes genome editing as a promising technique that is still under study.
An approved product for one disorder says nothing about whether a different cell or gene product will work for another, and approval status is the reliable marker of where a particular product stands, not marketing language.
Safety follow-up also differs in emphasis. The FDA’s gene therapy page cites its guidance on long-term follow-up after administration of human gene therapy products, a reminder that altering genes is a step that calls for monitoring well beyond the treatment itself. For cell products, attention falls on the source of the cells, how they were processed and whether they are the patient’s own or a donor’s.
For readers following trial news, the practical point is to check what the product actually is before comparing it with another. A gene-editing study and a stem cell infusion study answer different scientific questions, even when both are described in headlines as regenerative medicine.
How to tell the two apart in practice
A few plain questions sort most products. Is genetic material being added, removed, silenced or repaired? Then it is a gene therapy. Are intact living cells being given as the active component? Then it is a cell therapy. Are a patient’s cells being modified in the laboratory before they are returned? Then it is both.
The same questions help when reading news about investigational work. Whether a given approach is suitable for any individual is a decision for a licensed physician who knows that person’s situation, and the FDA’s approved-product list is the place to check what has actually been authorized.
Frequently asked questions
Is a stem cell treatment a gene therapy?
Show answer
Not by itself. A stem cell product is a cellular therapy product, and it becomes a gene therapy only when the cells are genetically modified before use.
Who regulates these products in the United States?
Show answer
The FDA’s Center for Biologics Evaluation and Research regulates both cellular therapy products and human gene therapy products.
What is genome editing and how does it differ from gene addition?
Show answer
Gene addition introduces new genetic material into cells, while genome editing introduces molecular tools that change the DNA already in the cell, according to MedlinePlus.
Do gene therapies require a special application before human studies?
Show answer
Yes. The FDA requires an investigational new drug application before clinical studies begin in the United States, and a biologics license application is needed to market the product.
